BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang R, Chen J, Liu D, Wang Y. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats. Front Med 2019;13:398-408. [DOI: 10.1007/s11684-019-0689-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Gracia-sancho J, Caparrós E, Fernández-iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:411-31. [DOI: 10.1038/s41575-020-00411-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
2 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Nassour H, Iddir M, Chatenet D. Towards Targeting the Urotensinergic System: Overview and Challenges. Trends in Pharmacological Sciences 2019;40:725-34. [DOI: 10.1016/j.tips.2019.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Alqahtani SA, Jang S. Pathophysiology and Management of Variceal Bleeding. Drugs 2021;81:647-67. [PMID: 33710585 DOI: 10.1007/s40265-021-01493-2] [Reference Citation Analysis]
5 Pereira-Castro J, Brás-Silva C, Fontes-Sousa AP. Novel insights into the role of urotensin II in cardiovascular disease.Drug Discov Today. 2019;24:2170-2180. [PMID: 31430542 DOI: 10.1016/j.drudis.2019.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]